The effect of Atomoxetine on Cognitive Function of Multiple Sclerosis

INTERVENTION: Intervention 1: Intervention group: The intervention group consisted of 26 patients who will be treated with Atomoxetine capsules at a dose of 40 mg daily for 2 weeks and then increased to 80 mg daily to 40 mg twice daily for It will take three months. Intervention 2: The control group consisted of 26 patients who will be treated with placebo‐like Atomoxetine capsules once daily for 2 weeks and then increased twice daily for three months. CONDITION: G37.9 Multiple Sclerosis. ; Demyelinating disease of central nervous system, unspecified PRIMARY OUTCOME: Cognitive Disorder Score in MacFims Questionnaire. Timepoint: Perform MacFims test at the beginning of the study and three months after the start of the study. Method of measurement: MacFims Questionnaire. SECONDARY OUTCOME: Accompanying depression score. Timepoint: At the beginning of the study and 3 months later. Method of measurement: Beck Questionnaire. INCLUSION CRITERIA: Diagnosis of Multiple Sclerosis based on McDonald's criteria Age between 18 to 55 years Testable Measurable Cognitive impairment (MACFIMS) attributed to Multiple Sclerosis